Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
talicabtagene autoleucel
- Development stage
- Unknown
- Lead developer
- ImmunoACT
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Talicabtagene autoleucel is a humanized anti-CD19 chimeric antigen receptor (CAR) T-cell therapy developed for the treatment of relapsed/refractory B-cell malignancies. It consists of autologous T cells from the patient that have been genetically modified to express a humanized anti-CD19 CAR. The therapy is administered as a single intravenous infusion and has demonstrated high response rates in clinical trials for patients with relapsed/refractory B-cell lymphomas and acute lymphoblastic leukemia. Talicabtagene autoleucel was first approved in India in October 2023 for these indications[3][5][2].
- Brand names
- NexCAR19NexCAR-19NexCAR 19
- Other names
- actaly-celactalycabtagene autoleucel
02
Targets
Beyond the preview
Go deeper on talicabtagene autoleucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on talicabtagene autoleucel.